Genvor Incorporated filed a current report on October 26, 2026, disclosing that on October 22, 2026, the company entered into an Intellectual Property Assignment Agreement with its Chief Scientific Officer and co-founder, Dr. Jesse Jaynes, covering approximately 9,000 antimicrobial peptide sequences and associated research data.

Key Highlights

  • IP Assignment Agreement: Genvor Incorporated entered into an Intellectual Property Assignment Agreement with Dr. Jesse Jaynes, dated October 21, 2026, and executed on October 22, 2026.
  • Assignor role: Dr. Jaynes is identified in the filing as one of the company's founders, a director, and the company's Chief Scientific Officer.
  • Scope of assignment: The agreement covers the rights to synthetic and designed peptide sequences, including approximately 9,000 antimicrobial peptides referenced in the company's Annual Report for the fiscal year ended September 30, 2025.
  • Data transferred: According to the filing, the assignment also includes associated design, screening, activity, formulation, and validation data, as well as any unpublished design notes, rules, or selection criteria used by the company.
  • Emerging growth company: Genvor Incorporated is identified in the filing as an emerging growth company under applicable SEC rules.
  • Signed by CEO: The report was signed by Chad Pawlak, Chief Executive Officer, on October 26, 2026.

Genvor Formalizes Ownership of Antimicrobial Peptide Library from Founder Jaynes

According to the filing, Genvor Incorporated, a Nevada-incorporated company headquartered in Henderson, Nevada, is engaged in research, development, and commercialization programs involving synthetic and designed antimicrobial peptides. The company's work with these peptides had previously relied on sequences and associated data provided by Dr. Jesse Jaynes, who had been serving as a founder, director, and Chief Scientific Officer prior to the agreement.

The Intellectual Property Assignment Agreement, filed as Exhibit 10.1, formally transfers to Genvor the rights to approximately 9,000 antimicrobial peptides that were referenced in the company's Annual Report on Form 10-K for the fiscal year ended September 30, 2025. The filing notes that the assignment also encompasses the design, screening, activity, formulation, and validation data tied to those sequences, along with any unpublished design notes, rules, or selection criteria that were provided to or used by the company in its programs. Certain schedules to the agreement have been omitted from the public filing pursuant to Item 601(a)(5) of Regulation S-K, though the filing states copies may be furnished to the SEC upon request, subject to potential confidential treatment under Rule 24b-2.

The filing states that the description of the Assignment Agreement "does not purport to be complete and is qualified in its entirety by reference to the full text of the Assignment Agreement." No financial terms of the agreement are disclosed in the filing. Securities registered pursuant to Section 12(b) of the Act are listed as none, and no exchange-listed trading symbol appears in the filing's registered-securities table.

What Was Disclosed

Genvor Incorporated disclosed the execution of an Intellectual Property Assignment Agreement with CSO and co-founder Dr. Jesse Jaynes, covering approximately 9,000 antimicrobial peptide sequences and related research data previously used in the company's development programs.